These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 17926831)
21. [What to remember about prevention and screening]. Davin JL Soins; 2007 Mar; (713):56. PubMed ID: 17419580 [No Abstract] [Full Text] [Related]
22. Gynecologic cancers. Blair AR; Casas CM Prim Care; 2009 Mar; 36(1):115-30, ix. PubMed ID: 19231605 [TBL] [Abstract][Full Text] [Related]
23. To screen or not to screen? Prostate cancer screening: why it's not for every man. Lefevre M Medscape J Med; 2008; 10(8):181. PubMed ID: 18924633 [No Abstract] [Full Text] [Related]
24. Prostate cancer screening: why it's not for every man. Lakhan SE Medscape J Med; 2008; 10(8):182; author reply 182. PubMed ID: 18924634 [No Abstract] [Full Text] [Related]
25. In this issue: mini-theme on geriatric care and cancer screening. Bowman MA; Neale AV J Am Board Fam Med; 2009; 22(3):231-3. PubMed ID: 19429726 [No Abstract] [Full Text] [Related]
26. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Schröder FH; Bangma CH; Roobol MJ Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712 [TBL] [Abstract][Full Text] [Related]
27. How should PSA screening efforts be focused to prevent underdiagnosis and overdiagnosis of prostate cancer? Pelzer AE; Horninger W Nat Clin Pract Urol; 2008 Apr; 5(4):172-3. PubMed ID: 18317497 [No Abstract] [Full Text] [Related]
28. What's new in prostate cancer screening and prevention? Klein EA Cleve Clin J Med; 2009 Aug; 76(8):439-45. PubMed ID: 19652036 [TBL] [Abstract][Full Text] [Related]
29. The future of cancer screening. Collins LG; Wynn DT; Barash JH Prim Care; 2009 Sep; 36(3):623-39. PubMed ID: 19616158 [TBL] [Abstract][Full Text] [Related]
30. Should men over the age of 65 years receive PSA screening? Argument in favor. Whitson JM; Konety BR Nat Clin Pract Urol; 2008 May; 5(5):230-1. PubMed ID: 18349861 [No Abstract] [Full Text] [Related]
34. What to do with an abnormal PSA test. Loeb S; Catalona WJ Oncologist; 2008 Mar; 13(3):299-305. PubMed ID: 18378540 [TBL] [Abstract][Full Text] [Related]
35. Re: Is a screening interval of every 4 years for prostate cancer acceptable? Roobol MJ; Schröder FH J Natl Cancer Inst; 2008 Feb; 100(3):222; author reply 223-4. PubMed ID: 18230797 [No Abstract] [Full Text] [Related]
36. Mass screening-based case-control study of diet and prostate cancer in Changchun, China. Li XM; Li J; Tsuji I; Nakaya N; Nishino Y; Zhao XJ Asian J Androl; 2008 Jul; 10(4):551-60. PubMed ID: 18478158 [TBL] [Abstract][Full Text] [Related]
37. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer. Boscolo-Berto R Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655 [No Abstract] [Full Text] [Related]
38. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker. Hamilton RJ; Platz EA; Freedland SJ J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913 [No Abstract] [Full Text] [Related]
39. Proteins' promise--progress and challenges in ovarian cancer proteomics. Koehn H; Oehler MK Menopause Int; 2007 Dec; 13(4):148-53. PubMed ID: 18088525 [TBL] [Abstract][Full Text] [Related]
40. Unrealistic expectations in the diagnosis and treatment of ovarian cancer. Kirchner JT N Engl J Med; 1993 Mar; 328(9):663-4. PubMed ID: 8429864 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]